Related Experiment Video
Updated: Feb 26, 2026

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
[News in diabetology 2016]
1Service d'endocrinologie, diabétologie, hypertension et nutrition , HUG, 1211 Genève 14.
Abstract:
The field of diabetes is constantly evolving, with numerous new molecules reaching the market in the treatment of type 2 diabetes. Paradoxically, this drug jungle is difficult for the primary care physician and can lead to therapeutic inertia. After the beneficial effect of empagliflozin on cardiovascular outcomes in the EMPA REG Outcome trial in 2015, liraglutide also shows cardiovascular benefits in high risk patients with type 2 diabetes. Therefore, these two studies, led to new recommendations by the Swiss Society for Endocrinology and Diabetes, by notably favouring the prescription of these molecules to type 2 diabetic patients in secondary prevention, after metformin.
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Psychoneuroimmunology: Diabetes and Cancer

